Katia Grillone

Catanzaro, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 32 publications

UMG1 Defines a Targetable Subset of T-Cell Lymphomas and Enables Precision Immunotherapy With a First-in-Class CD3ε Bispecific Engager.

UMG1 Defines a Targetable Subset of T-Cell Lymphomas and Enables Precision Immunotherapy With a First-in-Class CD3ε Bispecific Engager.

Journal: Hematological oncology

Published: September 24, 2025

A systematic review of non-coding RNA therapeutics in early clinical trials: a new perspective against cancer.

A systematic review of non-coding RNA therapeutics in early clinical trials: a new perspective against cancer.

Journal: Journal of translational medicine

Published: May 22, 2024

TERRA G-quadruplex stabilization behind the anti-multiple myeloma activity: Novel insights about resveratrol pleiotropic effects.

TERRA G-quadruplex stabilization behind the anti-multiple myeloma activity: Novel insights about resveratrol pleiotropic effects.

Journal: Archiv der Pharmazie

Published: April 10, 2024

LNA-i-miR-221 activity in colorectal cancer: A reverse translational investigation.

LNA-i-miR-221 activity in colorectal cancer: A reverse translational investigation.

Journal: Molecular therapy. Nucleic acids

Published: December 31, 2023

Non-Invasive Prenatal Test Analysis Opens a Pandora's Box: Identification of Very Rare Cases of SRY-Positive Healthy Females, Segregating for Three Generations Thanks to Preferential Inactivation of the XqYp Translocated Chromosome.

Non-Invasive Prenatal Test Analysis Opens a Pandora's Box: Identification of Very Rare Cases of SRY-Positive Healthy Females, Segregating for Three Generations Thanks to Preferential Inactivation of the XqYp Translocated Chromosome.

Journal: Genes

Published: December 11, 2023

UMG1/CD3ε-bispecific T-cell engager redirects T-cell cytotoxicity against diffuse large B-cell lymphoma.

UMG1/CD3ε-bispecific T-cell engager redirects T-cell cytotoxicity against diffuse large B-cell lymphoma.

Journal: British journal of haematology

Published: August 19, 2023

An unbiased lncRNA dropout CRISPR-Cas9 screen reveals RP11-350G8.5 as a novel therapeutic target for multiple myeloma.

An unbiased lncRNA dropout CRISPR-Cas9 screen reveals RP11-350G8.5 as a novel therapeutic target for multiple myeloma.

Journal: Blood

Published: August 17, 2023

Targeting non-coding RNAs: Perspectives and challenges of in-silico approaches.

Targeting non-coding RNAs: Perspectives and challenges of in-silico approaches.

Journal: European journal of medicinal chemistry

Published: July 25, 2023

Lynch Syndrome Biopathology and Treatment: The Potential Role of microRNAs in Clinical Practice.

Lynch Syndrome Biopathology and Treatment: The Potential Role of microRNAs in Clinical Practice.

Journal: Cancers

Published: June 20, 2023

Hit identification of novel small molecules interfering with MALAT1 triplex by a structure-based virtual screening.

Hit identification of novel small molecules interfering with MALAT1 triplex by a structure-based virtual screening.

Journal: Archiv der Pharmazie

Published: March 06, 2023

A Pronectin™ AXL-targeted first-in-class bispecific T cell engager (pAXLxCD3ε) for ovarian cancer.

A Pronectin™ AXL-targeted first-in-class bispecific T cell engager (pAXLxCD3ε) for ovarian cancer.

Journal: Journal of translational medicine

Published: February 20, 2023

The First-In-Class Anti-AXL×CD3ε Pronectin™-Based Bispecific T-Cell Engager Is Active in Preclinical Models of Human Soft Tissue and Bone Sarcomas.

The First-In-Class Anti-AXL×CD3ε Pronectin™-Based Bispecific T-Cell Engager Is Active in Preclinical Models of Human Soft Tissue and Bone Sarcomas.

Journal: Cancers

Published: February 13, 2023

Showing 1-12 of 32

Last Updated: 09/26/2026